Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
ESMO Open|March 5, 2022
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trialS Senan, M Özgüroğlu, D Daniel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trialH M Dhillon, M L Bell, H P van der Ploeg, et al.
Oncogene|April 19, 2011
C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancerY Shi, J Chen, Z Li, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancerE H Tan, A Szczesna, M Krzakowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factorsD Goldstein, M L Bell, P Butow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Oncogene|September 25, 1998
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalR Hui, J R Ball, R D Macmillan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Pageof 8